Catalog No.
DHC19529
Expression system
Mammalian Cells
Species reactivity
Human
Clonality
Monoclonal
Target
Alpha-D-galactosidase A, Galactosylgalactosylglucosylceramidase GLA, GLA, Melibiase, Agalsidase, Alpha-D-galactoside galactohydrolase, Alpha-galactosidase A
Concentration
2.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Purified by Ion Exchange Chromatography.
Accession
P06280
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CAS: 104138-64-9
Clone ID
Fabrazyme
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study, PMID: 29437868
Agalsidase Alfa, PMID: 30601613
Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal), PMID: 22878505
Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal), PMID: 22498845
Fabry Disease Therapy: State-of-the-Art and Current Challenges, PMID: 33379210
Successful management of enzyme replacement therapy in related fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme(®)) to agalsidase alfa (replagal (®)), PMID: 24718841
Enzyme replacement therapy for Anderson-Fabry disease, PMID: 27454104
Genetics and Gene Therapy of Anderson-Fabry Disease, PMID: 29618309
Agalsidase alfa: a review of its use in the management of Fabry disease, PMID: 22946754
Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease, PMID: 23430546
Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety, PMID: 19236256
Altered immune phenotypes in subjects with Fabry disease and responses to switching from agalsidase alfa to agalsidase beta, PMID: 30972193
Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued, PMID: 32561366
Agalsidase alfa--a preparation for enzyme replacement therapy in Anderson-Fabry disease, PMID: 12036428
Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature, PMID: 27608175
The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts, PMID: 30775256
Treatment switch in Fabry disease- a matter of dose?, PMID: 32522756
Switch from agalsidase beta to agalsidase alfa in the enzyme replacement therapy of patients with Fabry disease in Latin America, PMID: 28643672
Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa, PMID: 24388678
Agalsidase Beta, PMID: 29999661
Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease, PMID: 26303609
[The switch of enzyme therapy in Fabry disease], PMID: 25098458
Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg, PMID: 17622343
Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?, PMID: 25010055
Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice, PMID: 16372133
Enzyme replacement therapy for Anderson-Fabry disease, PMID: 23450571
Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Naïve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa, PMID: 25822820
Update on role of agalsidase alfa in management of Fabry disease, PMID: 21552486
Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients, PMID: 28592315
Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies, PMID: 28296917
Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina, PMID: 23335703
Anderson-Fabry disease in children, PMID: 23448455
Effect of reduced agalsidase Beta dosage in fabry patients: the Australian experience, PMID: 23430871
Fabry disease, enzyme replacement therapy and the significance of antibody responses, PMID: 22037707
Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages, PMID: 29186537
Enzyme replacement therapy for Anderson-Fabry disease, PMID: 20464743
Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease, PMID: 19707338
Efficacy of enzyme replacement therapy in Fabry disease, PMID: 15320778
Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval, PMID: 15268683
Renal complications of Fabry disease, PMID: 23448456
Recommendations on reintroduction of agalsidase Beta for patients with fabry disease in europe, following a period of shortage, PMID: 23430520
Enzyme replacement therapy of Fabry disease, PMID: 16077182
Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?, PMID: 24886109
Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta, PMID: 18701330
Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature, PMID: 22963910
Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy, PMID: 33072516
Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase, PMID: 26252393
The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease, PMID: 17700388
Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations, PMID: 20345350
Gateways to clinical trials, PMID: 15672123
For research use only. Not for human or drug use.
